Physician profile
Patrick Mccabe
NPI 1659798650
$4,758.39
in general payments reported to CMS, 2019-2025
19 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.75 · 2020: $35.09 · 2021: $302 · 2022: $193 · 2023: $620 · 2024: $1,666 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,032 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,031.75 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.29 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $605.53 | 2022-2025 | Entyvio |
| Gilead Sciences, INC. | $589.95 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $547.66 | 2020-2025 | Xifaxan, Plenvu |
| Genzyme Corporation | $376.24 | 2023-2025 | |
| Janssen Biotech, INC. | $307.42 | 2023-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $284.24 | 2024-2025 | Resmetirom, Rezdiffra |
| Ardelyx, INC. | $207.30 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $170.16 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $120.44 | 2023 | Wegovy |
| Aimmune Therapeutics, INC. | $86.35 | 2025 | Zenpep, Vowst |
| Janssen Scientific Affairs, LLC | $77.92 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $57.09 | 2025 | Iqirvo |
| Pfizer INC. | $57.09 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $42.27 | 2023-2024 | Dificid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $38.77 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $22.56 | 2025 | Voquezna |
| Boston Scientific Corporation | $18.61 | 2024 | |
| Celltrion USA INC. | $16.50 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.